Lilly will acquire Kelonia, a spinout from the laboratory of Michael Birnbaum. Kelonia is developing treatments for a variety of diseases with its in vivo gene editing platform, including a single-infusion CAR-T cancer therapy that showed robust, sustained responses across all patients in early clinical trials.
Wall Street Journal | Boston Globe | STAT News | CNBC